Coronavirus disease (COVID-19) is an infectious disease caused by the coronavirus SARS-CoV-2. Here we have collected APR news related to the COVID-19 pandemic, vaccination efforts and emerging treatments.
The FDA issued an emergency use authorization for Pemgarda (pemivibart) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents (12 years of age and older weighing ...
read more
Monday, February 05, 2024
CSL and Arcturus Therapeutics announced the results of a follow-up analysis of a Phase 3 study evaluating a booster dose of ARCT-154, the world's first approved self-amplifying messenger RNA (sa-mRNA)...
read more
In December 2021, FDA authorized Paxlovid for emergency use for the treatment of adults and pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression ...
read more
Tuesday, December 19, 2023
Novavax, Inc. announced that the Taiwan FDA granted emergency use authorization for Nuvaxovid™ XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) for active ...
read more
Tuesday, November 28, 2023
Novavax, Inc. announced that Nuvaxovid™ XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) was granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunization to prevent COVID-...
read more
Monday, November 06, 2023
Revive Therapeutics entered into a license agreement with Lawson Health Research Institute for the worldwide exclusive rights to novel blood biomarkers that characterize long COVID.
read more
Friday, November 03, 2023
The FDA is advising healthcare providers who administer the Moderna COVID-19 Vaccine (2023-2024 Formula) to individuals 6 months through 11 years of age to ensure that the correct volume of the ...
read more
Thursday, October 26, 2023
Pfizer Inc. and BioNTech SE announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates ...
read more
Wednesday, October 18, 2023
Novavax announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (U.K.) has granted full marketing authorization for its prototype COVID-19 vaccine Nuvaxovid...
read more
Fall is usually a good time for tradeshows and conferences. And, after nearly three years of not attending any events due to COVID, I’m back at many of the shows.
It’s actually good to be back, it ...
read more
Thursday, September 28, 2023
Pfizer Canada ULC and BioNTech SE announced that Health Canada has authorized the companies' Omicron XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY® Omicron XBB.1.5) for ages 6 months and ...
read more
Monday, September 18, 2023
BioNTech and the Coalition for Epidemic Preparedness Innovations (CEPI) announced a strategic partnership to advance mRNA-based vaccine candidates with the development of BNT166 for the prevention of...
read more
Wednesday, August 30, 2023
Pfizer and BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended marketing authorization for the companies’ Omicron XBB.1...
read more
Novavax announced that its updated protein-based XBB COVID vaccine candidate induced neutralizing antibody responses to the EG.5.1 and XBB.1.16.6 subvariants in small animal and non-human primate ...
read more
Thursday, August 03, 2023
PrecisionLife has announced the results of its long COVID study, providing the first detailed genetic insights into the condition and its commonalities with other diseases, including myalgic ...
read more